Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer

CONCLUSIONS: Our results identify MIR652-3p as potential biomarker and as a driver of cell and non-cell autonomous mechanisms of resistance to regorafenib.PMID:38376926 | DOI:10.1158/1078-0432.CCR-23-2748

Source: Clinical Colorectal Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Somaieh Hedayat Luciano Cascione David Cunningham Marta Schirripa Andrea Lampis Jens C Hahne Nina Tunariu Sung Pil Hong Silvia Marchetti Khurum Khan Elisa Fontana Valentina Angerilli Mia Delrieux Daniel Nava Rodrigues Letizia Procaccio Sheela Rao David Wa Source Type: research